QUEENSBURY, N.Y. - Delcath Systems, Inc. (NASDAQ:DCTH), a company specializing in interventional oncology treatments, has announced the successful exercise of Series E and E1 warrants, which provided the company with $16.3 million in funding. This financial move comes after the warrants, part of a private placement from July and August 2019, reached their expiration on December 24, 2024. According to InvestingPro data, the company has demonstrated remarkable growth with revenue surging by 946% in the last twelve months, though it currently maintains a moderate market capitalization of $382 million.
The exercise of the warrants, which had a set price of $10.00 per share, is expected to bolster the company's commercialization efforts and support its clinical development plans. Gerard Michel, CEO of Delcath, stated that this additional funding, alongside their current cash and anticipated revenue growth, positions them well for advancing their commercial strategies and investing in new clinical trials. InvestingPro analysis shows the stock has delivered an impressive 187.5% return year-to-date, with analysts setting price targets between $18 and $25.
Delcath's primary focus is the development of treatments for primary and metastatic liver cancers. Their proprietary products, HEPZATO KIT™ and CHEMOSAT® Hepatic Delivery System for Melphalan, are designed to administer high-dose chemotherapy directly to the liver while minimizing systemic exposure and side effects.
In the United States, the HEPZATO KIT is approved by the FDA as a liver-directed treatment for adult patients with metastatic uveal melanoma that has unresectable hepatic metastases. In Europe, the CHEMOSAT system is approved as a Class III medical device used to treat a variety of liver cancers.
The company has emphasized that the information provided in this announcement is based on a press release statement and that these forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Delcath has cautioned that the statements should not be relied upon as guarantees of future performance and that they are subject to various factors, some of which may be beyond the company's control.
In other recent news, Delcath Systems has demonstrated robust growth in its Q3 2024 results, with total revenue reaching $11.2 million, largely driven by its Hepzato kit sales. This success led to a $25 million financing boost from warrant exercises, leaving the company with a strong financial position, evidenced by $14 million in cash and no outstanding debt. Clear Street recently initiated a Buy rating on Delcath Systems, highlighting the company's potential for profitability, particularly through its Hepzato product. The analyst firm's confidence in Delcath's future performance is mirrored in its set price target of $22.00.
The initiation by Clear Street aligns with the broader analyst consensus, which ranges from $18 to $25. Delcath Systems is also planning to expand its treatment centers and initiate new clinical trials for liver-dominant metastatic colorectal and breast cancers. The company currently operates 12 treatment centers, with a goal of having 30 centers by the end of 2025.
In terms of future expectations, Delcath Systems is on track to reach cash flow break-even, supported by anticipated revenue growth. The enrollment for new clinical trials for colorectal and breast cancers is expected to start in mid-2025 and late-2025 respectively. These are among the latest developments for Delcath Systems.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.